

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 471/06, A61K 31/335, C07D 491/06 // (C07D 471/06, 221:00, 209:00) (C07D 491/06, 265:00, 241:00)	A1	(11) International Publication Number: WO 95/11903 (43) International Publication Date: 4 May 1995 (04.05.95)
(21) International Application Number: PCT/US94/11544 (22) International Filing Date: 11 October 1994 (11.10.94) (30) Priority Data: 142,748 25 October 1993 (25.10.93) US		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: ORTHO PHARMACEUTICAL CORPORATION [US/US]; U.S. Route #202, Raritan, NJ 08859 (US). (72) Inventors: BAXTER, Ellen, W.; 148 North Keswick Avenue, Glenside, PA 19038 (US). REITZ, Allen, B.; 109 Greenbriar Road, Lansdale, PA 19446 (US). (74) Agents: CIAMPORCERO, Audley, A., Jr. et al.; Johnson and Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).		

(54) Title: TRICYCLIC COMPOUNDS HAVING AFFINITY FOR THE 5-HT1A RECEPTOR



(57) Abstract

Compounds represented by general formula (I) having affinity for the 5-HT1A receptor are disclosed as useful in treating diseases of the central nervous system.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TRICYCLIC COMPOUNDS HAVING AFFINITY FOR THE 5-HT_{1A} RECEPTOR5 **BACKGROUND OF THE INVENTION**

Compounds which modulate serotonergic receptors are known to have a therapeutic use in man for the treatment of anxiety, schizophrenia, depression, convulsions, migraine, insomnia, and other diseases of the central nervous system.


10 Further, such ligands may be useful in treating cardiovascular disorders such as hypertension (e.g. *J. Med. Chem.* 1992, **35**, 3058-3066). Partial agonists of the serotonin-1A (5-HT_{1A}) receptor have been found to be useful for the treatment of anxiety; a compound of this type is buspirone, marketed as an anxiolytic (*Med. Chem. Rev.* 1990, **10**, 283-326; *Annu. Rev. Med.* 1990, **41**, 437-446). In addition,

15 compounds modulating the 5-HT_{1A} site may be useful as antiagressives or serenics (*Drug News Perspect.* 1990, **3**, 261-271).

Compounds having some structural similarity to those of the present invention are described in European Patents 463691 and 485952, World Patents 20 9119719, 9304682, and 9304684 as well as Rao, V. A.; Jain, P. C.; Anand, N. *Ind. J. Chem.* 1969, **7**, 833, Rao, V. A.; Jain, P. C.; Anand, N.; Srimal, R. C.; Dua, P. R. *J. Med. Chem.* 1970, **13**, 516, Gupta, S. P.; Chatterjee, S. S.; Bindra, J. S.; Jain, P. C.; Anand, N. *Ind. J. Chem.* 1975, **13**, 462, Kumar, N.; Jain, P. C.; Anand, N. *Ind. J. Chem.* 1979, **17B**, 244, Huff, J. R.; King, S. W.; Saari, W. S.; Springer, J. P.; Martin, G. E.; Williams, M., *J. Med. Chem.* 1985, **28**, 1945; Russell, M. G. N.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Noble, A. J. *J. Med. Chem.* 1992, **35**, 2025.

SUMMARY OF THE INVENTION


30 The present invention is directed to compounds represented by the general formula I:



wherein R¹, R², R³, R⁴, X, Y, Z and n are as defined hereinafter. Such compounds are a novel structural class which have potent affinity for the 5-HT_{1A} receptor and may thus be expected to be useful in treating anxiety, aggression, schizophrenia, depression, convulsion migraines, insomnia and other diseases of the central nervous system.

DETAILED DESCRIPTION OF THE INVENTION

More particularly, the present invention is directed to compounds represented by the general formula I:



I

R¹ and R² are independently selected from any of H, halogen, C₁-C₆ alkoxy, C₁-C₆ alkyl or trifluoromethyl. More preferably, each of R¹ and R² is H.


X is O when n is 1 and X is NH when n is 0.

Y is CH₂.

n is 0 or 1.

Z is N when X is O or Z is C when X is NH.

R³ and R⁴ are independently selected from any of H, C₁-C₆ alkyl, C₁-C₈ acyl, provided that R³ and R⁴ can not be C₁-C₈ acyl at the same time, or may be taken together to form together with the N a monocyclic 5-7 membered saturated ring or a 5-7 membered ring fused to an aromatic ring aryl. More preferably, R³ and R⁴ are taken together to form together with the N a 6 membered saturated ring with carbon atoms at the other 5 ring positions or a bicyclic ring structure of the formula:



The substitution pattern in the amide-bearing aromatic ring is ortho, meta, or para.

5

As used herein alkyl and alkoxy include straight and branched chains. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *t*-butyl, *n*-pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, *n*-hexyl, 1-methylpentyl, 3-methylpentyl. Alkoxy radicals are oxygen

10 ethers formed from the previously described straight or branched chain alkyl groups. The term "independently" is used with respect to aryl and ring substituents to indicate that when more than one of such substituents is possible such substituents may be the same or different from each other. The term "aryl," as used herein alone or in combination with other terms, indicates aromatic

15 hydrocarbon groups such as a phenyl or naphthyl group.

Examples of particularly preferred compounds are:

1-(3-(2-(1,2,3,4-Tetrahydro-9H-pyrido(3,4-b)indolyl)methyl)benzoyl)piperidine;

20

1-(3-(2-(1,2,3,4-Tetrahydro-9H-pyrido(3,4-b)indolyl)methyl)benzoyl)indoline;

1-(3-(1-(1,2,3,4,4a,5-Hexahdropyrazino(1,2-c)-1,4-benzoxazinyl)methyl)benzoyl)-piperidine; and

25

1-(3-(3-(1,2,3,4,4a,5-Hexahdropyrazino(1,2-c)-1,4-benzoxazinyl)methyl)benzoyl)-indoline.


The definition of formula I includes racemates and individual isomers; e.g., as caused by the presence of an asymmetric carbon such as when a substituent would be 2-butyl. Also within the scope of the invention are compounds of the invention in the form of hydrates and other solvate forms.

Representative salts of the compounds of formula I which may be used include those made with acids such as hydrochloric, hydrobromic, hydroiodic,

perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, 5 benzenesulfonic, *p*-toluenesulfonic, cyclohexanesulfamic, salicylic, *p*-amino-salicylic, 2-phenoxybenzoic, 2-acetoxybenzoic or a salt made with saccharin. Such salts can be made by reacting the free base of formula I with the acid and recovering the salt.

The compounds of Formula I may be prepared according to the Reaction
10 Scheme 1:

Reaction Scheme 1




15 Tricyclic amines 1 can be reacted with a halomethylbenzamide 2 (wherein A is a halogen) to afford compound 3. These condensations can be carried out in THF or a polar aprotic solvent such as DMSO or DMF in the presence of a base such as triethylamine or potassium carbonate and generally requiring heating from about 30 - 80°C.

20 Tricyclic compounds 1 are either commercially available or may be prepared as shown in Reaction Scheme 2. Phthalimide 4 (Gupta, S. P. et al. *Ind. J. Chem.* 1975, 13, 462) can be converted to benzoxazine 5 using standard catalytic hydrogenation conditions with Raney nickel or palladium on carbon. Cleavage of 25 the phthalimido group can be effected with hydrazine in a refluxing alcoholic solvent such as ethanol to provide diamine 6. Condensation with benzylchloroformate can be carried out in an aprotic solvent such as tetrahydrofuran or dichloromethane with a base such as triethylamine or pyridine


present. These additions are usually done at a low temperature (-78°C to 0°C), and then the reaction mixture is allowed to warm to ambient temperature. The subsequent reaction with chloroacetyl chloride can be conducted under the same reaction conditions to provide 7. Ring closure of 7 can be effected with mild base such as potassium carbonate in a polar aprotic solvent such as N,N-dimethylformamide or dimethyl sulfoxide at room temperature. Reduction of the lactam can be achieved with a borane reagent such as a borane-tetrahydrofuran complex in tetrahydrofuran as solvent. Removal of the carbobenzyloxy group can be done under transfer hydrogenation conditions such as 1,4-cyclohexadiene with palladium on carbon with acid in an aqueous alcoholic solvent system to give 8.

Reaction Scheme 2



Preparation of halomethylbenzamides 2 can be achieved as shown in Reaction Scheme 3. An amine and halomethylbenzoyl chloride (wherein A is a halogen) are combined at about 0°C in an aprotic solvent such as tetrahydrofuran or dichloromethane and the mixture is then allowed to warm to about 25°C to ensure complete reaction.

Reaction Scheme 3



5 The final products are preferably chromatographed to achieve purity and are then converted to an acceptable salt form.

To prepare the pharmaceutical compositions of this invention, one or more compounds or salts thereof of the invention, as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.

Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain per dosage unit; e.g., tablet, capsule, powder, injection, teaspoonful and the like, from about 50 to about 100 mg of the active ingredient.





In therapeutic use as an agent useful in treating diseases of the central nervous system in mammals, particularly humans, the compounds utilized in the pharmaceutical method of this invention are administered to the patient at dosage levels of from about 0.1 to 10 mg/kg per day. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition

being treated, the particular disease being treated and the compound being employed. Determination of optimum dosages for a particular situation is within the skill of the art.

5 The testing results of representative compounds of this invention are listed in Table 1, in binding at the dopamine-2 (D₂) and 5-HT_{1A} receptors. As can be seen in data shown in Table 1, there is weak or no activity at the D₂ site, whereas there is pronounced binding to the 5-HT_{1A} site.

10

TABLE 1

Compound	Receptor Binding, (K _i , nM)	
	D-2	5-HT _{1A}
	374	13
	>1000	9.2
	>1000	12
	>1000	6.5

Receptor Binding Assay

The dopamine D₂ and serotonin 5-HT_{1A} binding activity of compounds was determined using a P₂ fraction (synaptosomal membranes) prepared from male, 5 Wistar rats. The D₂ assay employed a P₂ fraction from the striatum, the ligand ³H-spiperone at a concentration of 0.05 nM, and 1 nM haloperidol as a blank determinant. Incubation was in 3 mM potassium phosphate buffer having a pH of 7.5 for 45 min at 37°C. Under these conditions, specific binding constituted 75% of total binding, and the K_I values for some known drugs were: 0.37 nM for 10 haloperidol and 82 nM for clozapine.

The 5-HT_{1A} assay used a P₂ fraction from the cerebral cortex, the ligand ³H-8-hydroxy-DPAT at a concentration of 3 nM, and 1 mM serotonin as a blank 15 determinant. Incubation was in 3 mM potassium phosphate buffer having a pH of 7.5 for 20 min at 25°C. Under these conditions, specific binding constituted 85% of total binding, and the K_I values for some known drugs were: 0.32 nM for WB4101, 59 nM for phentolamine, and 111 nM for clozapine.

The data from each assay were analyzed by calculating the percent inhibition of 20 the binding of the tritiated ligands by given concentrations of the test compound. K_I values, where given, were obtained from the logit analysis of concentration-inhibition curves.

EXAMPLES

25

Example 1: 1-(3-(2-(1,2,3,4-Tetrahydro-9H-pyrido(3,4-b)indolyl)methyl)-benzoyl)piperidine Monooxalate 0.3 Hydrate (9)

To an ice-cooled solution of piperidine (67.6 g, 0.793 mole) in tetrahydrofuran 30 (1L) was added dropwise a solution of 3-chloromethylbenzoyl chloride (100.0 g, 0.529 mmol). When the addition was complete, the reaction mixture was allowed to warm to ambient temperature and was left to stir overnight. The reaction mixture was poured into a solution of 1N hydrochloric acid. This solution was extracted with diethyl ether. The ether extracts were combined, washed with water, dried 35 (MgSO₄), and concentrated to afford 108.7 g (86%) of N-(3-(chloromethyl)benzoyl)piperidine (10) as a pale yellow oil whose ¹H NMR in CDCl₃ supported the structure.

To a solution of 1,2,3,4-tetrahydro-9*H*-pyrido(3,4-*b*)indole (2.50 g, 14.5 mmol) in 50 mL of tetrahydrofuran was added benzyl chloride **10** (4.14 g, 17.4 mmol) in 50 mL of tetrahydrofuran followed by triethylamine (1.91 g, 18.9 mmol). This suspension was refluxed under nitrogen for 30 h. After cooling, the reaction mixture was poured into 1N hydrochloric acid and diethyl ether. The layers were separated, and the aqueous solution was basified with solid potassium carbonate and then extracted with chloroform. The chloroform extracts were combined, dried (Na_2SO_4), and concentrated to afford an orange-brown oil which was purified by column chromatography on flash silica gel (chloroform to 5% methanol-chloroform) to provide a yellow foam. This material was dissolved in methanol, and oxalic acid (0.81 g) was added followed by diethyl ether and hexanes. A buff-colored solid was collected which was recrystallized from methanol and ether to provide 1.41 g (21%) of **9** as a beige powder, mp 173-181°C. The ^1H NMR in DMSO-d_6 supported the assigned structure. ^1H NMR δ 1.50 (br m, 4 H), 1.61 (br s, 2 H), 2.84 (br s, 2 H), 3.15 (br s, 2 H), 3.28 (br s, 2 H), 3.59 (br s, 2 H), 3.92 (s, 2 H), 4.12 (s, 2 H), 6.95-7.07 (m, 2 H), 7.28-7.55 (m, 6 H).

Elemental analysis: Calculated for $\text{C}_{24}\text{H}_{27}\text{N}_3\text{O} \cdot 1.0\text{C}_2\text{H}_2\text{O}_4 \cdot 0.3\text{H}_2\text{O}$: C, 66.59; H, 6.36; N, 8.96; H_2O , 1.15. Found C, 66.19; H, 6.32; N, 9.08; H_2O , 0.81.

Example 2: 1-(3-(2-(1,2,3,4-Tetrahydro-9*H*-pyrido(3,4-*b*)indolyl)methyl)-benzoyl)indoline Monofumarate (11)

To an ice-cooled solution of indoline (1.50 g, 12.6 mmol) and triethylamine (1.66 g, 16.3 mmol) in tetrahydrofuran (50 mL) was added dropwise 3-chloromethylbenzoyl chloride (2.86 g, 15.1 mmol). When the addition was complete, the reaction mixture was allowed to warm to ambient temperature and was left to stir overnight. The reaction mixture was poured into saturated sodium bicarbonate solution. This solution was extracted with chloroform. The chloroform extracts were combined, washed with water, dried (Na_2SO_4), and concentrated to afford 3.23 g (79%) of a pale yellow oil of N-(3-(chloromethyl)benzoyl)indoline (**12**) whose ^1H NMR in CDCl_3 supported the structure.

To a solution of 1,2,3,4-tetrahydro-9*H*-pyrido(3,4-*b*)indole (3.11 g, 18.1 mmol) in tetrahydrofuran (100 mL) was added benzyl chloride **12** (6.50 g, 23.9 mmol) in tetrahydrofuran (100 mL) followed by triethylamine (4.57 g, 45.2 mmol). This suspension was refluxed under nitrogen for 2.5 days. After cooling, the reaction mixture was poured into 1N hydrochloric acid and diethyl ether. The layers were separated; the ether extract was washed with saturated sodium bicarbonate

solution, dried ($MgSO_4$), and concentrated to provide a beige foam. The aqueous solution was basified with solid potassium carbonate and then extracted with chloroform. The chloroform extracts were combined, dried (Na_2SO_4), and concentrated to afford a beige foam. Since both materials appeared to contain the desired product, they were combined and purified by column chromatography on flash silica gel (chloroform) to provide a brown foam. This material was dissolved in methanol, and fumaric acid (0.76 g) was added followed by diethyl ether and hexanes. A cream-colored precipitate was collected which was recrystallized from acetone to provide 2.03 g (21%) of 11 as a buff-colored powder, mp 215-217°C.

10 The 1H NMR in $DMSO-d_6$ supported the assigned structure. 1H NMR δ 2.70 (br m, 2 H), 2.84 (br t, 2 H), 3.09 (t, J = 8.2 Hz, 2 H), 3.61 (br s, 2 H), 3.82 (br s, 2 H), 4.02 (t, J = 8.2 Hz, 2 H), 6.62 (s, 2 H), 6.90-7.02 (m, 3 H), 7.12 (br s, 1 H), 7.26 (m, 3 H), 7.35 (d, J = 7.5 Hz, 1 H), 7.50-7.57 (m, 3 H).

15 Elemental analysis: Calculated for $C_{27}H_{25}N_3O \cdot 1.0 C_2H_2O_4$: C, 71.11; H, 5.58; N, 8.03. Found C, 70.96; H, 5.56; N, 8.44.

20 **Example 3: 1-(3-(1,2,3,4,4a,5-hexahydropyrazino(1,2-c)-1,4-benzoxazinyl)methyl)benzoyl)piperidine Sesquioxalate (13)**

The preparation of 3-aminomethyl-1,4-benzoxazine (6) was carried out by the method of Gupta et al. (*Ind. J. Chem.* 1975, 13, 462) with the following modification. Reduction of the nitro group with concomitant reductive amination was conducted with 10% palladium on charcoal rather than Raney nickel.

25 A solution of diamine 6 (1.80 g, 11.0 mmol) and triethylamine (1.66 g, 16.4 mmol) in tetrahydrofuran (100 mL) was cooled to -78°C under nitrogen. To this solution was added dropwise benzylchloroformate (2.24 g, 13.2 mmol) in tetrahydrofuran (100 mL). When the addition was complete, the reaction mixture 30 was allowed to warm slowly to ambient temperature. After 3 days of stirring, the reaction mixture was poured into saturated sodium bicarbonate solution which was extracted with chloroform. The chloroform extracts were combined, dried (Na_2SO_4), and concentrated to provide the desired carbamate as 3.80 g (quantitative yield) of a dark brown oil whose 1H NMR in $CDCl_3$ supported the expected structure. This material was taken on without further purification.

A solution of the carbamate (3.80 g, 12.8 mmol) and triethylamine (2.19 g, 21.7 mmol) in dichloromethane (250 mL) was cooled to -78°C under nitrogen. To this solution was added dropwise chloroacetyl chloride (1.73 g, 15.3 mmol) as a

solution in dichloromethane (100 mL). When the addition was complete, the reaction mixture was slowly warmed to ambient temperature. After stirring overnight, the reaction mixture was poured into water. The layers were separated, and the organic layer was washed with 1N hydrochloric acid, dried (Na_2SO_4), and 5 concentrated to give 4.77 g (97%) of chloroacetamide 7 as a brown foam. The ^1H NMR in CDCl_3 supported the structure. This material was carried on to the next reaction without further purification.

A suspension of chloroacetamide 7 (4.65 g, 12.4 mmol) and potassium carbonate (5.40 g, 39.1 mmol) in dimethyl sulfoxide (300 mL) was stirred under nitrogen at ambient temperature. After 16 h, the reaction mixture was poured into water and extracted several times with ethyl acetate. The ethyl acetate extracts were combined, washed with water several times, dried (MgSO_4), and concentrated to provide a brown foam. Purification was done using column chromatography on flash silica gel (MeOH/chloroform, 0:100 to 1:99) to provide 15 1.45 g of the expected lactam as a yellow foam. A second purification on flash silica gel (chloroform) afforded an additional 0.44 g of the desired lactam. The ^1H NMR in CDCl_3 supported the structure.

20 A solution of the above lactam (1.44 g, 4.26 mmol) in tetrahydrofuran (100 mL) was cooled to 0°C under nitrogen, and a 1M solution of borane-tetrahydrofuran complex (21.3 mL, 21.3 mmol) was added dropwise. When the addition was complete, the reaction mixture was allowed to warm to ambient 25 temperature. After 16 h of stirring, the reaction mixture was cooled in ice and diluted with water. A few drops of 1N HCl were added, and then the reaction mixture was basified with solid potassium carbonate. The resulting suspension was extracted with chloroform. The chloroform extracts were combined, dried (Na_2SO_4), and concentrated to provide 1.45 g (quantitative yield) of the desired tricyclic amine carbamate as a colorless oil which solidified on standing. The ^1H 30 NMR in CDCl_3 supported the structure. This material was carried on to the next reaction without further purification.

To an ice-cooled solution of the aforementioned carbamate (1.31 g, 4.04 mmol) in 230 mL of 9:1 (v/v) methanol-water was added 10% palladium on carbon 35 (1.31 g), 1,4-cyclohexadiene (3.24 g, 40.4 mmol), and trifluoroacetic acid (1.38 g, 12.1 mmol). The reaction mixture was slowly warmed to ambient temperature under nitrogen. After 16 h, the reaction mixture was filtered through dicalite, and the filtrate was concentrated to give a pale-green solid. To this material was added 10% aqueous sodium carbonate solution which was subsequently extracted

several times with chloroform. The chloroform extracts were combined, dried (Na_2SO_4), and concentrated to provide 0.64 g (83%) of tricyclic amine **8** as a golden brown oil. The ^1H NMR in CDCl_3 supported the assigned structure. This material was carried on to the next reaction without further purification.

5

To a solution of tricyclic amine **8** (0.96 g, 5.05 mmol) in tetrahydrofuran (50 mL) was added N-(3-(chloromethyl)benzoyl)piperidine (**10**, 1.44 g, 6.06 mmol) as a solution in tetrahydrofuran (50 mL). Triethylamine (0.77 g, 7.57 mmol) was added, and the reaction mixture was refluxed under nitrogen for 2 days. The 10 reaction mixture was cooled and 1N hydrochloric acid solution and diethyl ether were added. The layers were separated, and the aqueous solution was basified with solid potassium carbonate and then extracted with chloroform. The chloroform extracts were combined, dried (Na_2SO_4), and concentrated to afford a red-brown oil. This material was purified by flash column chromatography on silica gel 15 (MeOH/chloroform, 0:100 to 2:98) to afford 0.73 g of **13** as an iridescent yellow foam. This material was dissolved in acetone and oxalic acid-dihydrate (0.35 g) was added. After diethyl ether was added, a cloudy solution resulted which was treated with hexanes to give a fluffy cream-colored precipitate. This solid was recrystallized from acetone/ether to provide two crops of product which were 20 combined to afford 0.33 g (12%) of **13** as a cream-colored powder, mp 168-172°C (decomposition). The ^1H NMR in DMSO-d_6 supported the assigned structure. ^1H NMR δ 1.50 (br m, 4 H), 1.61 (m, 2 H), 2.02 (m, 1 H), 2.45 (m, 1 H), 2.96 (br d, 1 H), 3.04 (br d, 1 H), 3.10 (br t, 2 H), 3.25 (br s, 2 H), 3.55 (br s, 2 H), 3.68-3.92 (m, 4 H), 4.23 (br d, $J = 8.4$ Hz, 1 H), 6.60-6.92 (m, 4 H), 7.28-7.48 (m, 4 H).

25

Elemental analysis: Calculated for $\text{C}_{24}\text{H}_{29}\text{N}_3\text{O}_2 \cdot 1.5 \text{ C}_2\text{H}_2\text{O}_4$: C, 61.59; H, 6.13; N, 7.98. Found C, 61.64; H, 6.21; N, 7.98.

30

Example 4: 1-(3-(3-(1,2,3,4,4a,5-Hexahydropyrazino(1,2-c)-1,4-benzoxazinyl)-methyl)benzoyl)indoline 1,2 Oxalate (14)


To a solution of tricycle **8** (1.15 g, 6.04 mmol) in tetrahydrofuran (100 mL) was added N-(3-(chloromethyl)benzoyl)indoline (**12**, 1.97 g, 7.25 mmol) as a solution in tetrahydrofuran (100 mL). Triethylamine (1.53 g, 15.1 mmol) was added, and the 35 reaction mixture was refluxed under nitrogen for 20 h. Analysis by thin layer chromatography indicated that a considerable amount of unreacted starting material was present so additional triethylamine (1.53 g) was added. After 24 h of additional reflux, the reaction appeared to be complete. The reaction mixture was cooled and 1N hydrochloric acid solution and diethyl ether were added. The layers

were separated, and the ether extract was washed with saturated sodium bicarbonate solution, dried ($MgSO_4$), and concentrated to provide a dark brown oil. The hydrochloric acid solution was basified with solid potassium carbonate and then extracted with chloroform. The chloroform extracts were combined, dried (5 Na_2SO_4), and concentrated to afford a brown foam. Thin layer chromatographic analysis indicated that both materials contained desired product so they were combined and purified by flash column chromatography on silica gel (MeOH/chloroform, 0:100 to 1:99) to afford a brown oil. This oil was repurified three times on flash silica gel using pure chloroform as the eluant to provide a golden 10 brown oil which was dissolved in acetone and oxalic acid-dihydrate (0.35 g) was added. When diethyl ether and then hexanes were added, a fluffy cream colored precipitate fell out of solution. This solid was recrystallized from acetone to provide 0.37 g (11%) of 14 as a snow-white powder, mp 197.5-198.5°C. The 1H NMR in DMSO-d₆ supported the assigned structure. 1H NMR δ 2.00 (br t, 1 H), 2.35 (m, 1 15 H), 2.69 (br t, 1 H), 3.93 (br d, 1 H), 3.00 (br d, 1 H), 3.09 (br t, 3 H), 3.64-3.92 (m, 3 H), 3.88 (br t, 1 H), 4.02 (br t, 2 H), 4.21 (br d, J = 8.5 Hz, 1 H), 6.60-6.72 (m, 3 H), 6.75 (br t, 1 H), 6.86 (br d, J = 7.4 Hz, 1 H), 7.03 (br d, 1 H), 7.26 (br m, 1 H), 7.28 (d, J = 7.5 Hz, 1 H), 7.48-7.62 (br m, 4 H).

20 Elemental analysis: Calculated for $C_{27}H_{27}N_3O_2 \cdot 1.2 C_2H_2O_4$: C, 65.88; H, 5.98; N, 7.83. Found C, 66.16; H, 5.60; N, 7.61.

WE CLAIM:

1. A compound represented by the general formula I:



5

wherein R¹ and R² are independently selected by any of H, halogen, C₁-C₆ alkoxy, C₁-C₆ alkyl or trifluoromethyl;

10

X is O when n is 1 and X is NH when n is 0;

wherein Y is CH₂;

15

wherein n is 0 or 1;

wherein Z is N when X is O and Z is C when X is NH;

20

wherein R³ and R⁴ are independently selected from any of H, C₁-C₆ alkyl, C₁-C₈ acyl, provided that R³ and R⁴ can not both be C₁-C₈ acyl at the same time or may be taken together to form with the N a monocyclic 5-7 membered saturated ring or a 5 membered ring fused to an aromatic ring;

25

or the racemates, individual isomers, hydrates, solvates or acid addition salts thereof.


2. The compound of claim 1, wherein R¹ and R² are each H.

3. The compound of claim 1, wherein X is O and n is 1.

30

4. The compound of claim 1, wherein X is NH and n is 0.

5. The compound of claim 1, wherein R³ and R⁴ are taken together with the N to form a 6 membered saturated ring or together with the N to form a bicyclic ring structure of the formula:



6. The compound of claim 1, wherein R³ and R⁴ are taken together to form with the N a 6 membered saturated ring.

5

7. The compound of claim 1, wherein the compound is selected from any of:

1-(3-(2-(1,2,3,4-Tetrahydro-9H-pyrido(3,4-b)indolyl)methyl)benzoyl)piperidine;

10

1-(3-(2-(1,2,3,4-Tetrahydro-9H-pyrido(3,4-b)indolyl)methyl)benzoyl)indoline;

1-(3-(1-(1,2,3,4,4a,5-Hexahydropyrazino(1,2-c)-1,4-benzoxazinyl)methyl)benzoyl)piperidine; or

15

1-(3-(3-(1,2,3,4,4a,5-Hexahydropyrazino(1,2-c)-1,4-benzoxazinyl)methyl)benzoyl)indoline.

20

8. A pharmaceutical composition comprising the compound of claim 1, in combination with suitable pharmaceutical carrier, said compound being present in therapeutically effective amount for treating a diseases of the central nervous system.

25

9. A method of treating a disease of the central nervous system comprising administering to an animal afflicted with such a disease the compound of claim 1 in an amount sufficient to treat such disease.

10. The method of claim 9, wherein the disease is anxiety.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 94/11544

A. CLASSIFICATION OF SUBJECT MATTER
**IPC 6 C07D471/06 A61K31/335 C07D491/06 // (C07D471/06, 221:00,
 209:00), (C07D491/06, 265:00, 241:00)**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,90 06927 (ABBOTT LABORATORIES) 28 June 1990 ---	1-10
Y	WO,A,93 08166 (THE UPJOHN COMPANY) 29 April 1993 ---	1-10
Y	EP,A,0 539 209 (THE UPJOHN COMPANY) 28 April 1993 ---	1-10
Y	US,A,5 244 888 (DE BERNARDIS,J.F. ET AL.) 14 September 1993 ---	1-10
Y	US,A,5 049 564 (DE BERNARDIS,J.F. ET AL.) 17 September 1991 ---	1-10
Y	WO,A,91 13872 (THE UPJOHN COMPANY) 19 September 1991 ---	1-10
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 February 1995

Date of mailing of the international search report

24.02.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 94/11544

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,91 11435 (THE UPJOHN COMPANY) 8 August 1991 ---	1-10
Y	BE,A,849 919 (CARLO ERBA S.P.A.) 15 April 1977 ---	1-10
Y	IND.J.CHEM., vol.17B, March 1979 pages 244 - 245 KUMAR,N. ET AL. 'Agents acting on CNS: XXVII. Synthesis of 3-substituted 2,3,4,4a, ,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxali- ne' cited in the application ---	1-10
Y	IND.J.CHEM., vol.13, May 1975 pages 462 - 467 GUPTA,S.P. ET AL. 'Compounds Acting on XCN : XXII. Synthesis of 2,3,4,4a,5,6,-He- xahydro[2,1-c]-1,4-benzoxazines' cited in the application ---	1-10
Y	J.RECEPTOR RES., vol.11, no.1-4, 1991 pages 177 - 196 HANCOCK,A.A. ET AL. 'Molecular design of novel ligands for 5-HT1A receptors' * See in particular page 181, fig. 2 *	1-10
Y	NAUNYN-SCHMIEDEBERG'S ARCH.PHARMACOL., vol.343, 1991 pages 109 - 116 SLEIGHT,A.J. ET AL. 'Identification of 5-hydroxytryptamine 1A receptor agents using a composite pharmacophore analysis and chemical database screening' ---	1-10
Y	J.MED.CHEM., vol.35, no.13, 1992, WASHINGTON pages 2369 - 74 MOKROSZ,J.L. ET AL. 'SAR Studies of CNS Agents 5. Effect of the Hydrocarbon Chain on the affinity of ...' * see page 2369, formula 8 - 10 *	1-10
P,X	J.MED.CHEM., vol.37, no.1, 1994, WASHINGTON pages 105 - 112 MEYER,M.D. ET AL. 'Synthesis and Structure- Activity Relationships of cis- and trans-2 ,3,4,4a,9,9a-Hexahydro-1H-indeno[2,1-c]pyr- idines for 5-HT Receptor Subtypes' -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No	
PCT/US 94/11544	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9006927	28-06-90	AU-B-	626621	06-08-92
		AU-A-	4746090	10-07-90
		CA-A-	2005441	15-06-90
		EP-A-	0422134	17-04-91
		GR-B-	1001059	28-04-93
		JP-T-	3502701	20-06-91

WO-A-9308166	29-04-93	AU-A-	2559392	21-05-93
		EP-A-	0539209	28-04-93

EP-A-0539209	28-04-93	AU-A-	2559392	21-05-93
		WO-A-	9308166	29-04-93

US-A-5244888	14-09-93	US-A-	5049564	17-09-91
		GR-B-	1001059	28-04-93

US-A-5049564	17-09-91	GR-B-	1001059	28-04-93
		US-A-	5244888	14-09-93

WO-A-9113872	19-09-91	AU-B-	639536	29-07-93
		AU-A-	7303091	10-10-91
		CA-A-	2075057	16-09-91
		EP-A-	0594593	04-05-94
		US-A-	5302599	12-04-94

WO-A-9111435	08-08-91	AU-B-	639301	22-07-93
		AU-A-	7175491	21-08-91
		EP-A-	0510068	28-10-92
		JP-T-	5503698	17-06-93
		US-A-	5288748	22-02-94

BE-A-849919	15-04-77	AT-B-	358596	25-09-80
		AT-B-	355589	10-03-80
		AT-B-	351041	10-07-79
		AU-B-	504565	18-10-79
		AU-A-	2086376	29-06-78
		CA-A-	1099267	14-04-81
		CH-A-	630383	15-06-82
		DE-A-	2658806	14-07-77
		FR-A,B	2336929	29-07-77

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 94/11544

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
BE-A-849919		GB-A- 1533020 JP-A- 52083397 NL-A- 7614445 SE-A- 7613778 US-A- 4134974	22-11-78 12-07-77 04-07-77 01-07-77 16-01-79